SPONSOR

Memorial Sloan Kettering Cancer Center

Total Trials

Recruiting

Phases

Phase 2, Phase 1, Phase 3, EARLY_Phase 1, Phase 1, Phase 2

Conditions studied: Graft Versus Host Disease Graft Vs Host Disease Hematologic Malignancy Kidney Cancer Bladder Cancer Breast Cancer Lung Cancer Lung Cancer Stage II Lung Cancer Stage III Desmoplastic Small Round Cell Tumor

Memorial Sloan Kettering Cancer Center (MSK) is the world's oldest and largest private cancer center, located in New York City with regional outpatient locations across the greater New York and New Jersey area. MSK is an NCI-designated comprehensive cancer center and a major sponsor and site for investigator-initiated cancer clinical trials, with a particular emphasis on Phase 1 first-in-human studies, novel immunotherapy strategies, and precision oncology. MSK's research enterprise integrates laboratory science and clinical investigation more tightly than almost any other institution, allowing laboratory discoveries to be rapidly translated into clinical trials.

MSK is home to specialized programs in virtually every cancer type, including the Evelyn H. Lauder Breast Center, the David H. Koch Center for Cancer Care, the Josie Robertson Surgery Center, and the Parker Institute for Cancer Immunotherapy — a multi-institution collaboration that has advanced CAR-T cell therapy, cancer vaccines, and immune checkpoint research. MSK's Department of Medicine, Human Oncology and Pathogenesis Program (HOPP), and the Computational Oncology Program develop and test novel therapeutic hypotheses across a pipeline of early-phase trials.

Pharmacogenomics and genomics-driven trial design are central to MSK's research model. The institution uses the MSK-IMPACT tumor sequencing panel — a 505-gene next-generation sequencing assay — on virtually all tumor biopsies from patients seen at MSK, enabling enrollment in genotype-matched basket trials and providing a rich biomarker-linked clinical database. MSK was a founding member of the AACR Project GENIE consortium, which aggregates genomic and clinical data from 19 major cancer centers worldwide.

Frequently Asked Questions — Memorial Sloan Kettering Cancer Center

What Phase 1 clinical trials does Memorial Sloan Kettering offer?

MSK's Phase 1 Drug Development Program is one of the largest and most established in the United States, evaluating approximately 50–80 first-in-human or early-phase trials at any given time. These trials test novel small molecules, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, CAR-T and NK cell therapies, and cancer vaccines. Most Phase 1 trials at MSK require patients to have exhausted standard treatment options and to have good performance status. Eligibility is typically evaluated by MSK's Phase 1 team after review of medical records; referrals from outside physicians are accepted and encouraged.

What is MSK-IMPACT and how does it affect trial eligibility?

MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets) is a tumor sequencing assay that profiles 505 cancer-associated genes for mutations, copy number alterations, and structural rearrangements. Since 2014, MSK has performed MSK-IMPACT on tumor samples from nearly all patients treated at the center. The resulting genomic data is linked to clinical outcomes in the MSK cancer data platform (available via cBioPortal.org) and used to match patients to genomically-selected clinical trials — basket trials that enroll patients with a specific mutation regardless of tumor origin, such as BRAF, NTRK, RET, and HER2 alterations. Patients referred to MSK can often have their tumor sequenced as part of care.

Does MSK accept patients from outside New York for clinical trial enrollment?

Yes. MSK accepts referred patients from across the United States and internationally for clinical trial evaluation. Outpatient locations in New Jersey, Long Island, Westchester, and Connecticut expand access for regional patients. For patients traveling from farther away, MSK's Patient Access Service coordinates scheduling and provides recommendations for accommodations. Some trials — particularly immunotherapy infusion protocols — require patients to remain within a defined distance of MSK for safety monitoring during the initial treatment cycles. MSK social workers can help identify lodging assistance programs for patients in financial need.

Memorial Sloan Kettering Cancer Center

Frequently Asked Questions — Memorial Sloan Kettering Cancer Center

Clinical Trials by Memorial Sloan Kettering Cancer Center

A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant

A Study of a Side Effects and Resource Navigation Program for People With Cancer

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Registry to Collect Health Information About Desmoplastic Small Round Cell Tumor

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism

A Study of Methylprednisolone in People Having Liver Surgery

Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease

MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial

A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma

A Study of Herbal Supplements in Cancer Survivors With Constipation

Discovering New Genetic Markers in Adults and Children Who May Be At Risk for Hereditary Forms of Cancer

Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders

A Study of Hospital-at-Home for People Receiving Tarlatamab

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

Ulixertinib in People With Histiocytic Neoplasms

A Study of a One-Time Counseling Session to Help Reduce Depression, Anxiety, and Distress in People With Breast Cancer

Collection of Information to Better Understand Young Onset Colorectal Cancer

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer

A New Psychotherapy Intervention for Older Cancer Patients

ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer

A Study of Ivonescimab in People With Non-Small Cell Lung Cancer

Germ Cell Tumor and Testicular Tumor DNA Registry

A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

Study Assessing the Effects of Early Psychiatric Referral on Mental Health and Quality of Life in People With Sarcoma

Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

A Study of Avutometinib and Defactinib in People With Thyroid Cancer

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma

A Study of Surgery and Radiotherapy in People With Breast Cancer

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change